Verrica Pharmaceuticals Inc.
VRCA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $41 | $50 | $42 | $47 |
| - Cash | $21 | $15 | $30 | $46 |
| + Debt | $14 | $39 | $42 | $46 |
| Enterprise Value | $34 | $74 | $55 | $47 |
| Revenue | $14 | $13 | $3 | $0 |
| % Growth | 12.9% | 269.4% | 899.7% | – |
| Gross Profit | $13 | $12 | $3 | -$0 |
| % Margin | 92.3% | 97.3% | 87.7% | -81.7% |
| EBITDA | $2 | $3 | -$7 | -$14 |
| % Margin | 14% | 19.9% | -213.2% | -3,953.5% |
| Net Income | -$0 | $0 | -$10 | -$16 |
| % Margin | -1.9% | 1.6% | -283.3% | -4,709.9% |
| EPS Diluted | -0.03 | 0.022 | -1.03 | -2.41 |
| % Growth | -239.5% | 102.1% | 57.3% | – |
| Operating Cash Flow | $10 | -$10 | -$13 | -$16 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $10 | -$10 | -$13 | -$16 |